The MFDS announced that it is conducting consultations with the company for rapid domestic approval on overseas developed COVID-19 oral treatments on the verge of commercialization.

In the case of Molnupiravir, an oral treatment for MSD, the government plans to gradually introduce 404,000 people through a pre-purchase contract in February next year, which is expected to speed up discussions on the introduction of overseas COVID-19 treatments in Korea.

Kim Mi-jung, head of the pharmaceutical standards division at the MFDS, briefly met with reporters at Osong on the afternoon of the 9th and made the announcement.

Kim said, "In the case of oral treatments of MSD and Pfizer, we